NCT Number | Phases | Status | Tumor | Intervention1 | Intervention 2 | Intervention 3 | Intervention 4 | Treatment line | Gene state |
---|---|---|---|---|---|---|---|---|---|
NCT05614739 | Phase 1 | Recruiting | Urinary Bladder Neoplasms Neoplasm Metastasis Ureteral Neoplasms | LOXO-435 | LOXO-435 +Pembrolizumab | After standard therapies | FGFR3-altered | ||
NCT04601857 | Phase 2 | Recruiting | Advanced and Metastatic Urothelial Cancer | Futibatinib +Pembrolizumab | First-line | FGFR3 Mutation; FGFR1-4 Fusion/Rearrangement | |||
NCT02401542 | Phase 1/2 | Terminated | Locally Advanced or Metastatic Urothelial Cell Carcinoma Urinary Bladder Disease Urological Diseases | Vofatamab +Docetaxel | Docetaxel +Placebo | Vofatamab | Second or subsequent | FGFR3 Mutant/Fusion | |
NCT05267470 | Phase 1 | Recruiting | Squamous-Cell Non-Small-Cell Lung Cancer | Bemarituzumab +Docetaxel | Bemarituzumab | Bemarituzumab +Pembrolizumab +Carboplatin +Paclitaxel | Intervention 1: Second or subsequent Intervention2: Third or subsequent Intervention3: First or subsequent | FGFR2b Overexpression | |
NCT05564416 | Phase 2 | Recruiting | Localized Bladder Cancer | Erdafitinib | Erdafitinib +Atezolizumab | Neoadjuvant | FGFR2/3 Alterations | ||
NCT04604132 | Phase 1/2 | Completed | Gastric Adenocarcinoma | Derazantinib | Derazantinib +Paclitaxel +Ramucirumab | Derazantinib +Atezolizumab | Paclitaxel +Ramucirumab | Second or subsequent | FGFR2 Fusions/Rearrangements/Amplifications; FGFR1-3 Mutations/Short variants |
NCT05174650 | Phase 2 | Recruiting | Intrahepatic Cholangiocarcinoma | Atezolizumab +Derazantinib | First or Second line | FGFR2 Fusions/Rearrangements | |||
NCT05510427 | Phase 1 | Not yet recruiting | Cholangiocarcinoma Liver Cancer | Infigratinib +Atezolizumab +Bevacizumab | Second or subsequent | FGFR2 Fusion/Amplification | |||
NCT04045613 | Phase 1/2 | Completed | Urothelial Carcinoma | Derazantinib | Derazantinib +Atezolizumab | Derazantinib +/-Atezolizumab | Intervention 1: Second or subsequent Intervention2: First-line Intervention3: Second-line | FGFR1-3 Mutations/Short variants and Rearrangements/fusions | |
NCT05004974 | Phase 2 | Not yet recruiting | Advanced Non Small Cell Lung Cancer | Sintilimab +Pemigatinib | First-line | FGFR Mutation | |||
NCT03473743 | Phase 1/2 | Active, not recruiting | Urothelial Carcinoma | Erdafitinib +Cetrelimab | Erdafitinib +Cetrelimab +Cisplatin/Carboplatin | Erdafitinib | Intervention 1: Any line Intervention2/3: First-line | FGFR Alterations | |
NCT04828486 | Phase 2 | Recruiting | Advanced Hepatocellular Carcinoma | Futibatinib +Pembrolizumab | Second-line | FGF-19 Positive | |||
NCT03473756 | Phase 1b/2 | Active, not recruiting | Locally Advanced or Metastatic Urothelial Carcinoma | Rogaratinib + Atezolizumab | First-line | FGFR1/3 mRNA expression | |||
NCT02325739 | Phase 1/2 | Completed | Solid Malignancies | FGF401 | FGF401 +PDR001 | Intervention 1: After standard therapies Intervention2: Third or subsequent | |||
NCT02925533 | Phase 1 | Terminated | Bladder Cancer | Vofatamab +Pembrolizumab | Second or subsequent | ||||
NCT03123055 | Phase 1/2 | Terminated | Locally Advanced or Metastatic Urothelial Cell Carcinoma | Vofatamab | Vofatamab +Pembrolizumab | First-line | |||
NCT04003610 | Phase 2 | Terminated | Metastatic Urothelial Carcinoma Unresectable Urothelial Carcinoma | Pemigatinib +Pembrolizumab | Pembrolizumab | Gemcitabine +Carboplatin | First-line | ||
NCT04699643 | Phase 1/2 | Recruiting | Advanced Solid Tumors | EVER4010001 +Pembrolizumab | After standard therapies | ||||
NCT05111626 | Phase 3 | Recruiting | Gastric Cancer Gastroesophageal Junction Adenocarcinoma | Bemarituzumab +Nivolumab +mFOLFOX6 | Nivolumab +mFOLFOX6 +Placebo | First-line | |||
NCT05173142 | Phase 1/2 | Recruiting | Solid Tumor | HMPL-453 monotherapy | HMPL-453 + chemotherapy /anti-PD-1 mAb | After standard therapies | |||
NCT05253053 | Phase 1/2 | Recruiting | Advanced Solid Tumor | TT-00420 | TT-00420 +Atezolizumab | TT-00420 +nab-paclitaxel | After standard therapies | ||
NCT05322577 | Phase 1 | Recruiting | Gastric Cancer Gastroesophageal Junction Cancer | Bemarituzumab +CAPOX | Bemarituzumab +CAPOX +Nivolumab | Bemarituzumab +SOX +Nivolumab | First-line | ||
NCT05369286 | Phase 1 | Recruiting | Solid Tumor | MAX-40279-01 +Toripalimab |